VAL-083: An Important Biological Approach to Fighting Drug-Resistant Tumors

Demonstrating Potency in Clinical Trials

VAL-083 has been evaluated in more than 40 Phase I and Phase II clinical trials by the U.S. National Cancer Institute and was found to have anti-cancer activities against various cancers, including brain tumors and ovarian cancers.